AI assistant
AVADEL PHARMACEUTICALS PLC — Director's Dealing 2019
May 24, 2019
31920_dirs_2019-05-24_a15e9a1e-03d9-438a-acce-d06a0fa9a829.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AVADEL PHARMACEUTICALS PLC (AVDL)
CIK: 0001012477
Period of Report: 2019-05-22
Reporting Person: Ende Eric J (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-01-31 | ADSs | A | 27900 | — | Acquired | 27900 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-05-22 | Stock Option (right to buy) | $1.49 | A | 8057 | Acquired | 2029-05-22 | ADSs (8057) | Direct |
Footnotes
F1: The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
F2: Represents 27,900 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 01/31/2019; one-third (1/3) of the ADSs will vest on each of the first three anniversaries of the grant date.
F3: Options are exercisable as to 2,685 shares, 2,686 shares and 2,686 shares on May 22, 2020, May 22, 2021 and May 22, 2022, respectively.